BENLYSTA (belimumab)

**Product type:** Human Prescription Drug

**Active ingredient:** BELIMUMAB

**Strength:** 200 mg/mL

**Dosage form:** Solution

**Route:** Subcutaneous

**Labeler:** GlaxoSmithKline LLC

**Marketing category:** BLA (BLA761043)

**Pharmacologic class:** B Lymphocyte Stimulator-directed Antibody Interactions [MoA], B Lymphocyte Stimulator-specific Inhibitor [EPC], Decreased B Lymphocyte Activation [PE]